Estimation of hepatic repercussion in obesity and cardiometabolic risk

  1. Mª Teófila Vicente-Herrero 17
  2. Mª Victoria Ramírez-Iñiguez de la Torre 12
  3. Luisa Capdevila García 13
  4. Ana Victoria Bueno Atkinson 4
  5. Ángel Arturo López González 567
  1. 1 Obesity and work group-Asociación Española de especialistas en Medicina del Trabajo-AEEMT.
  2. 2 Occupational Health and safety Services of Correos, Albacete (Spain).
  3. 3 Occupational Health and safety Services MAPFRE, Valencia (Spain).
  4. 4 Occupational Health Nurse. MAPFRE-UBS Majadahonda. Madrid (Spain).
  5. 5 Occupational Health and safety Services Servei de Salut de les Illes Balears.
  6. 6 University School ADEMA, Palma de Mallorca (Spain).
  7. 7 ADEMA-HEALTH Group of the University Institute of Health Sciences-IUNICS Illes Balears (Spain).
Show affiliations +
Journal:
Academic Journal of Health Sciences: Medicina Balear

ISSN: 2255-0560

Year of publication: 2022

Volume: 37

Issue: 5

Pages: 93-98

Type: Article

DOI: 10.3306/AJHS.2022.37.05.93 DIALNET GOOGLE SCHOLAR lock_openIbdigital editor

Abstract

Introduction: Obesity is a global pandemic with cardiometabolic repercussions and increased risk in the development of non-alcoholic liver disease. The objective of this work is to relate the cardiometabolic risk in obesity with the risk of hepatic repercussion in the working population. Method: Cross-sectional descriptive study in 815 workers between March 2020-June 2021. The FLI-fatty liver index and FIB-4 Index for liver fibrosis calculators and their relationship with body mass index and cardiometabolic risk are used. Results: A greater presence of high FLI and FIB-4 values was found in groups with a higher level of cardiometabolic risk and with BMI at levels of overweight/obesity, with more unfavorable results in men. Conclusions: In workers with obesity and cardiovascular risk or metabolic syndrome, a higher risk of hepatic repercussion quantified with FLI and FIB-4 is detected.

Bibliographic References

  • Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016 Dec;45(4):571-579. doi: 10.1016/j.gtc.2016.07.012.
  • Healthy people 2030. https://health.gov/healthypeople/objectives-and-data/browse-objectives/overweight-and-obesity (accessed 2022, March 10,)
  • Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019 Mar;92:6-10. doi: 10.1016/j.metabol.2018.09.005. Epub 2018 Sep 22.
  • Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016 Jun;22(7 Suppl):s176-85
  • Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019 Mar;92:98-107. doi: 10.1016/j.metabol.2018.10.011. Epub 2018 Nov 3.
  • Ortega FB, Lavie CJ, Blair SN. Obesity and Cardiovascular Disease. Circ Res. 2016 May 27;118(11):1752-70. doi: 10.1161/CIRCRESAHA.115.306883.
  • Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017 Jan 3;127(1):1-4. doi: 10.1172/JCI92035. Epub 2017 Jan 3.
  • Lemieux I, Després JP. Metabolic Syndrome: Past, Present and Future. Nutrients. 2020 Nov 14;12(11):3501. doi: 10.3390/nu12113501.
  • Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1899-1912. doi: 10.1053/j.gastro.2019.12.054. Epub 2020 Feb 13.
  • Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014 Jul 28;20(28):9330-7. doi: 10.3748/wjg.v20.i28.9330.
  • World Health Organization 2020. Body mass index – BMI. Available at: https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi. (accessed 2022, March 10)
  • Vicente-Herrero MT, Ramírez-Iñiguez de la Torre MV, López González AA. Estimación del nivel de riesgo cardiometabólico en trabajadores con sobrepeso/obesidad durante la pandemia Covid-19. Estilo de vida y variables sociodemográficas. [Estimation of cardiometabolic risk in overweight or obese workers during Covid-19 pandemic. Life style and sociodemographic variables] Academic Journal of Health Sciences 2022/37 (3): 134-41.
  • Buitrago Ramírez F, Cañón Barroso L, Díaz Herrera N, Cruces Muro E, Bravo Simón B, Pérez Sánchez I. Comparación entre la tabla del SCORE y la función Framingham-REGICOR en la estimación del riesgo cardiovascular en una población urbana seguida durante 10 años [Comparison of the SCORE function chart and the Framingham-REGICOR equation to estimate the cardiovascular risk in an urban population after 10 years of follow-up]. Med Clin (Barc). 2006 Sep 16;127(10):368-73. Spanish. doi: 10.1157/13092437.
  • Registre Gironí del Cor. Validación de las tablas Framigrahm-Regicor [Validation of Framigrahm-Regicor tables] ;2022 https://regicor.cat/es/presentacion/tablas-de-framingham-regicor/
  • Grau M, Marrugat J. Risk Functions and the Primary Prevention of Cardiovascular Disease. Rev Esp Cardiol. 2008;61(4):404-16.
  • Taberner R. Calculadora multiplataforma para síndrome metabólico y riesgo cardiovascular en pacientes con psoriasis [Multiplatform application to determine presence of metabolic syndrome and cardiovascular risk in patients with psoriasis]. Actas Dermosifiliogr. 2012 Mar;103(2):111-9. Spanish. doi: 10.1016/j.ad.2011.11.003. Epub 2012 Jan 28.
  • Tutunchi H, Ebrahimi Mameghani M, Ostadrahimi A, Asghari Jafarabadi M. What are the optimal cut-off points of anthropometric indexes for prediction of overweight and obesity? Predictive validity of waist circumferemce, waist-to-hip and waist-to-height ratios. Health Promotion Perspectives 2020;10(2)142-7.
  • Bello Chavolla OY, Antonio Vila NE, Vargas Vázquez A, Viveros Ruiz TL, Almeda Valdes P, Gómez Velasco D, et al. Metabolic Score for Visceral Fat (METS-VF), a novel estimator of intra-abdominal fat content and cardio-metabolic health. Clin Nutr 2020;39(5):1613-20.
  • Vicente-Herrero MT, Ramírez-Iñiguez de la Torre MV, Capdevila García L, Partida-Hanon A, Reinoso-Barbero L, López González AA. Prevalence of overweight and obesity in Spanish working population along the Covid-19 pandemic. Adiposity indicators and related variables. Academic Journal of Health Sciences 2022/37 (1): 90-4
  • Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006 Nov 2;6:33. doi: 10.1186/1471-230X-6-33.
  • Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018 Feb;68(2):305-315. doi: 10.1016/j.jhep.2017.11.013. Epub 2017 Dec 2.
  • Ros E. The PREDIMED study. Endocrinol Diabetes Nutr 2017;64(2):63-6.
  • Ferreira-Pêgo C, Nissensohn M, Kavouras SA, Babio N, Serra-Majem L, Martín Águila A, et al. Beverage Intake Assessment Questionnaire: Relative Validity and Repeatability in a Spanish Population with Metabolic Syndrome from the PREDIMED-PLUS Study. Nutrients 2016;8(8):475.
  • Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35(8):1381-95.
  • Román Viñas B, Ribas Barba L, Ngo J, Serra Majem L. Validación en población catalana del cuestionario internacional de actividad física [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. Gac Sanit 2013;27(3):254-7.
  • Marques A, Peralta M, Naia A, Loureiro N, de Matos MG. Prevalence of adult overweight and obesity in 20 European countries, 2014. Eur J Public Health. 2018 Apr 1;28(2):295-300. doi: 10.1093/eurpub/ckx143.
  • Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol. 2017;960:1-17. doi: 10.1007/978-3-319-48382-5_1.
  • Piché ME, Poirier P, Lemieux I, Després JP. Overview of Epidemiology and Contribution of Obesity and Body Fat Distribution to Cardiovascular Disease: An Update. Prog Cardiovasc Dis. 2018 Jul-Aug;61(2):103-113. doi: 10.1016/j.pcad.2018.06.004. Epub 2018 Jun 28.
  • Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci. 2021 Apr 15;271:119220. doi: 10.1016/j.lfs.2021.119220. Epub 2021 Feb 13.
  • Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10(1):63-71. doi: 10.1586/17474124.2016.1099433. Epub 2015 Oct 15.
  • Castera L. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2015 Aug;35(3):291-303. doi: 10.1055/s-0035-1562948. Epub 2015 Sep 17.
Data source: Dialnet